What is the 13F Pro Quality Score for TXMD?

13F Pro ranks TherapeuticsMD, Inc. (TXMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TXMD's current score at https://13fpro.ai/company/TXMD (free sign-up required for the full ranking).

Where does 13F Pro source TXMD data?

All TherapeuticsMD, Inc. fundamentals and ownership data come directly from SEC EDGAR. TherapeuticsMD, Inc. files with the SEC under CIK 25743. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TXMD in?

TherapeuticsMD, Inc. (TXMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are TXMD's largest expenses?

TherapeuticsMD, Inc.'s latest 10-Q reports these as the largest expense items: General and administrative ($2.930M, -3.7% YoY); Depreciation and amortization ($0.189M, -1% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (six months ended June 30, 2026).

How often is TXMD research updated on 13F Pro?

TXMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TherapeuticsMD, Inc.(TXMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 25743 TXMD stock profile & AI dashboard →

13F Pro Quality Score

58.8/100

Rank #971 of 2,962 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TXMD Scores 59/100

exact factor attribution · 2026-09-11

TXMD's composite is driven by revenue growth and free cash flow, held back by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.1 pts

96th pct

Free cash flow

+7.4 pts

99th pct

Earnings quality

+4.8 pts

98th pct

Earnings growth

+0.3 pts

56th pct

Shareholder dilution

-0.9 pts

31th pct

Capital efficiency

-1.2 pts

38th pct

Institutional flow

-1.8 pts

14th pct

Profitability

-2.0 pts

37th pct

Scale

-6.9 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TXMD Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for TherapeuticsMD, Inc. (TXMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TXMD at 58.8/100 on a 32-signal composite quality model, placing it at rank #971 of 2,962 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), TherapeuticsMD, Inc. reports quarterly revenue of $869.0K, net income of $155.0K, an operating margin of -93.9%. Top institutional holders of TXMD by reported 13-F value include Rubric Capital Management, Clearline Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TXMD trades on the Nasdaq exchange and files with the SEC under CIK 25743. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TXMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TherapeuticsMD, Inc. directly from SEC EDGAR. TherapeuticsMD, Inc.'s 13F Pro composite quality score has ranged between 3 and 67 since 2022, currently 58.8 — an improving long-term trajectory across 19 quarterly and live scoring snapshots.

✦

Fun facts about TherapeuticsMD, Inc.

Quirks, history, and lore behind TXMD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · headquartered in Florida · focused on a single patient population.
2
The Numbers
A small-cap biotech that spent years burning cash on clinical development before commercializing its products — revenues measured in the tens of millions, not billions.
3
The History
Founded in the early 2000s, the company spent much of its first decade quietly developing drugs rather than selling them, filing with the FDA repeatedly before finally winning approvals.
4
The Secret
Its entire portfolio is built around women's health — specifically targeting menopause symptoms and related hormonal conditions that larger pharma companies long underserved.
5
The Lore
The company scored a rare hat trick, winning FDA approval for three hormone therapy products — patches, softgels, and vaginal rings — in a relatively short window, a pipeline flush for a company its size.
6
The Giveaway
Its name is basically a mission statement: therapeutics for MD — as in, women's medicine — and its ticker spells out exactly that focus for anyone paying attention.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving TXMD's Business? Latest 10-Q Breakdown

AI-extracted from TherapeuticsMD, Inc.'s 10-Q filed 2026-08-11 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

TherapeuticsMD recorded $1.6M in license revenue for H1 2026, up 18% YoY, but faces substantial doubt about going concern due to litigation with Mayne Pharma over $5.5M net working capital settlement and dependence on royalties from licensed products.

Biggest Revenue Drivers

License revenue – Mayne Pharma (IMVEXXY, BIJUVA, ANNOVERA, prenatal vitamins)$1.593M+18% YoY

Royalties and minimum annual royalties from exclusive U.S. license to Mayne Pharma for commercialization of licensed products at 8.0% on first $80M and 7.5% above, with $3.0M minimum annual royalty for 12 years.

License revenue – Knight and Theramex (IMVEXXY, BIJUVA international)Included in total revenue above

Knight commercializing in Canada (launched 2024); Theramex in Europe (began commercialization 2021); Israel transferred to Theramex in December 2024. Milestone revenue from Knight for IMVEXXY H1 2025 sales recognized in Q3 2026 ($365K CAD equivalent).

Biggest Revenue Drivers

Total revenue: $1.593M+18% YoY

License revenue – Mayne Pharma (IMVEXXY, BIJUVA, ANNOVERA, prenatal vitamins)$1.593M+18% YoY

License revenue – Knight and Theramex (IMVEXXY, BIJUVA international)Included in total revenue above

Largest Expense Items

General and administrative$2.930M-3.7% YoY

Decrease primarily due to lower professional fees and stock-based compensation costs.

Depreciation and amortization$0.189M-1% YoY

Entirely comprised of amortization of license rights and intangible assets (hormone therapy drug patents).

Margins: The company incurred a loss from operations of $1.539M for H1 2026 (vs. $1.976M in H1 2025), improved by 22% due to higher license revenues and lower write-offs and professional fees. However, other income (interest, sublease, miscellaneous) of $1.806M partially offset operating losses, resulting in net income of $250K.

Watch Items from the Filing

Substantial going-concern doubt: management states 'substantial doubt about ability to continue as a going concern for next twelve months' due to dependence on Mayne Pharma royalties, pending litigation, net working capital disputes, and potential need for additional financing.
Mayne Pharma litigation: filed lawsuit April 2025 for breach of contract, fraudulent inducement, and unjust enrichment over net working capital allowances; Mayne filed countersuit May 2025. Court stayed case pending dispute resolution as of May 20, 2026. Cannot estimate range of loss.
Net working capital contingency: company paid $5.5M to Mayne Pharma in December 2023 for certain trued-up amounts; disputes remain unresolved for payer rebates, wholesale distributor fees, and allowance for returns, with final determination pending.
Revenue concentration: 100% of H1 2026 license revenue derived from Mayne Pharma, Knight, and Theramex; royalty receivable of $3.394M short-term and $12.626M long-term (including minimum annual royalties) concentrated with these three partners.
Patent litigation: Mayne Pharma responsible for defense of IMVEXXY patents against generic challenges from Teva (filed 2020, litigation ongoing since April 2020) and Sun Pharma (filed July 2024); IMVEXXY Patents expire 2032–2033.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$869.0K

Net Income

Q2 2026

$155.0K

Operating Margin

Q2 2026

-93.9%

ROIC

Q2 2026

-12.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+71.6% YoY

$3.0MFY 2025

FY22 $70.0MFY23 $1.3MFY24 $1.8MFY25 $3.0M

Net Income

+73.9% YoY

$-569.0KFY 2025

FY22 $112.0MFY23 $-10.3MFY24 $-2.2MFY25 $-569.0K

Operating Income

+28.2% YoY

$-4.4MFY 2025

FY22 $1.2MFY23 $-8.5MFY24 $-6.1MFY25 $-4.4M

EPS (Diluted)

+73.7% YoY

$-0.05FY 2025

FY22 $11.96FY23 $-0.99FY24 $-0.19FY25 $-0.05

Total Assets

-3.0% YoY

$37.7MFY 2025

FY22 $90.5MFY23 $43.3MFY24 $38.8MFY25 $37.7M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.0M +71.6%	$1.8M +35.3%	$1.3M -98.1%	$70.0M +2619.1%	$2.6M -96.0%	$64.9M
Net Income	$-569.0K +73.9%	$-2.2M +78.8%	$-10.3M -109.2%	$112.0M +165.0%	$-172.4M +6.1%	$-183.5M
Operating Income	$-4.4M +28.2%	$-6.1M +28.3%	$-8.5M -815.6%	$1.2M +101.5%	$-79.6M +48.8%	$-155.5M
EPS (Diluted)	$-0.05 +73.7%	$-0.19 +80.8%	$-0.99 -108.3%	$11.96 +155.2%	$-21.66	—
Total Assets	$37.7M -3.0%	$38.8M -10.4%	$43.3M -52.1%	$90.5M -46.6%	$169.5M -6.7%	$181.6M
Total Debt	—	—	—	—	$376.5M +58.4%	$237.7M
Operating Cash Flow	—	—	—	—	$-142.7M +10.5%	$-159.5M
Free Cash Flow	—	—	—	—	$-142.7M +10.6%	$-159.7M

Get alerted when TXMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TherapeuticsMD, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TXMD

Rubric Capital Management LP
$2.6M1,192,191 sh
Clearline Capital LP
$1.4M635,222 sh
VANGUARD CAPITAL MANAGEMENT LLC
$781.7K353,697 sh
Tejara Capital Ltd
$761.3K344,482 sh
ADAR1 Capital Management, LLC
$756.8K342,447 sh
RENAISSANCE TECHNOLOGIES LLC
$324.0K146,599 sh
MORGAN STANLEY
$285.6K129,217 sh
BlackRock, Inc.
$254.5K115,145 sh
GEODE CAPITAL MANAGEMENT, LLC
$234.0K105,849 sh
CITADEL ADVISORS LLC
$190.3K86,095 sh

Fund	Value	Shares
Rubric Capital Management LP	$2.6M	1,192,191
Clearline Capital LP	$1.4M	635,222
VANGUARD CAPITAL MANAGEMENT LLC	$781.7K	353,697
Tejara Capital Ltd	$761.3K	344,482
ADAR1 Capital Management, LLC	$756.8K	342,447
RENAISSANCE TECHNOLOGIES LLC	$324.0K	146,599
MORGAN STANLEY	$285.6K	129,217
BlackRock, Inc.	$254.5K	115,145
GEODE CAPITAL MANAGEMENT, LLC	$234.0K	105,849
CITADEL ADVISORS LLC	$190.3K	86,095

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TXMD on your watchlist

Track score changes the day TherapeuticsMD, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TXMD a good stock to buy?

13F Pro's AI-powered analysis of TherapeuticsMD, Inc. (TXMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TXMD are available on the TXMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TXMD is classified as a small company.

Which hedge funds own TXMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TXMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TherapeuticsMD, Inc.'s investment landscape.